Japanese R&D reinvigorated with international partnerships proliferating26 Mar 2019
Generics consumption increasing, and the removal of long-list products is opening up funding towards true innovation.
CPhI Japan closes as a new wave of innovation is rising across the country, driven by structural and regulatory changes. A focus on removing long-list products, and the increased use of generics has seen capital re-directed into R&D – with Takeda-Shire now possessing the world’s second largest pipeline of drug targets.
In a ground-breaking session at the event, Ian Haydock, Editor-In-Chief, Asia Pacific Informa Intelligence, highlighted how Japan has taken a lead in providing a supporting regulatory environment for orphan indications through its AMED programme. In addition, Japan is simultaneously emerging as a particularly prominent ecosystem for cell and gene therapy innovators.
What is most significant about the trends highlighted at CPhI Japan is that a consensus seems to be emerging for the removal of long-listed products. Long promoted as an anti-innovation strategy, it is increasingly viewed as an approach that is helping redirect capital towards the most innovative targets.
Highlighting the increased internalization in the market, the event also saw a landmark announcement with Swiss listed DKSH partnering with Novo Nordisk to distribute the company’s Quats (quaternary ammonium compounds) in Japan – which act as preservatives or active ingredients in a diverse range of pharmaceuticals applications.
“More than in any past event, this year we saw how Japan is very much becoming a centre for international trade, not only for Japanese companies looking to expand overseas but also for international companies looking for both domestic and international partners to help further their strategies across the entire APAC region,” commented Laura Murina, Brand Manager CPhI Japan.
Crucially, this internationalization is being observed both ways – inbound and outbound – and is highlighted on the exhibition floor. In total, Japan’s largest pharma trade event (18-20 March 2019 at the Big Sight Exhibition Centre, Tokyo), played host to almost 20,000 pharma professionals alongside 571 exhibitors from 29 countries, up from 450 just 3 years ago. These included major suppliers of pharmaceutical ingredients, packaging, contract services, as well as machinery, technology, and new in 2019, digital and IT companies in the Pharma IT & Digital Expo.
Beyond the exhibition, thousands of pharma professionals attended the CPhI Japan Conference, with keynote insights from Dr Isao Teshirogi, President of The Federation of Pharmaceutical Manufacturers’ & Association (IFPMA). The Japan Pharmaceutical Traders’ Association delivered the API International Procurement Forum 2019, which explored harmonization approaches and how to deliver greater international partnerships.
APIC (Active Pharmaceutical Ingredients Committee) provided an in-depth perspective for the Japanese market of the recent implementation of ICH Q3D in the EU and USA as a guideline for elemental impurities. The agreement discussed two approaches – the Drug Product and the Component Approach. In reality, however, the guidelines had a strong focus on the component approach moving forward.
Laura Murina added: “The success of the event strengthened the vital connections, partnerships and knowledge needed for the Japanese market to undergo structural changes necessary to deliver increased innovation. Raising the use of generics has provided opportunities for both domestic and international big pharma and manufacturers.”
Liquid pharmaceuticals in the digital age
30 May 2019
Inspiration, innovation and technical highlights from Bosch Packaging Technolgy's Pharmatag 2019.Read more
CPhI China opens with analysis pointing to a surge in growth in 2019
28 May 2019
Regulatory reforms and harmonisation reported as key drivers of industry in China.Read more
Expert forecasts huge growth in Middle East manufacturing
16 May 2019
UAE consumers and insurance companies are willing to pay for highest quality drug products.Read more
Lessons learned from early EU FMD adopters
13 May 2019
Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.Read more
Manufacturing growth sees surging demand at CPhI South East Asia
3 May 2019
Number of visitors seeking a contract manufacturer was extremely high, with multinational corporations increasingly looking for local partners to expedite market access into the wider region.Read more
Sirio’s Ayanda launches probiotic softgel
23 Apr 2019
Patent-pending technology is the first ever to enable a softgel capsule to contain both probiotic bacteria and Omega 3 oil.Read more
Surge of Indian biosimilars market forecast in 2019
22 Apr 2019
India predicted to be one of the world’s ‘fastest growing bio’ hubs in 2019, fuelled by new biosimilars production.Read more
New China-based biotechs fueling growth in manufacturing across China
9 Apr 2019
New guidelines will see poorer quality manufacturers drop out of the market.Read more
BASF launches three new active ingredients derived from the rambutan tree
2 Apr 2019
The ingredients are extracted from the first organically certified rambutan gardens in Vietnam.Read more
Sizeable growth potential for global drug delivery and packaging in 2019
19 Mar 2019
Patient-centricity, eco-friendly and smart packaging trends marked as the biggest growth drivers and innovations in 2019.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation